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Identiﬁcation of rare de novo epigenetic variations
in congenital disorders
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Certain human traits such as neurodevelopmental disorders (NDs) and congenital anomalies
(CAs) are believed to be primarily genetic in origin. However, even after whole-genome
sequencing (WGS), a substantial fraction of such disorders remain unexplained. We hypo-
thesize that some cases of ND–CA are caused by aberrant DNA methylation leading to
dysregulated genome function. Comparing DNA methylation proﬁles from 489 individuals
with ND–CAs against 1534 controls, we identify epivariations as a frequent occurrence in the
human genome. De novo epivariations are signiﬁcantly enriched in cases, while RNAseq
analysis shows that epivariations often have an impact on gene expression comparable to
loss-of-function mutations. Additionally, we detect and replicate an enrichment of rare
sequence mutations overlapping CTCF binding sites close to epivariations, providing a
rationale for interpreting non-coding variation. We propose that epivariations contribute to
the pathogenesis of some patients with unexplained ND–CAs, and as such likely have
diagnostic relevance.
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Epimutations represent a class of mutational event where theepigenetic status of a genomic locus deviates signiﬁcantlyfrom the normal state, and can be classiﬁed into two main
types: primary epimutations are thought to represent stochastic
errors in the establishment or maintenance of an epigenetic state,
while secondary epimutations are downstream events related to
an underlying change in the DNA sequence1. Both secondary and
primary epimutations that originate in the germline will be
constitutive events found in all cells. In contrast, primary epi-
mutations that occur post-fertilization may result in somatic
mosaicism. Constitutive (i.e., non-mosaic) epimutations are
known to underlie several genetic disorders that can be identiﬁed
in blood-derived DNA: 5–15% of patients with hereditary non-
polyposis colon cancer present with constitutional MLH1 pro-
moter methylation2, and fragile X syndrome, the most common
cause of inherited intellectual disability, results from a secondary
epimutation in which hypermethylation of an expanded CGG
repeat at the FMR1 promoter causes transcriptional silencing3.
With the recent dramatic advances in genomic technologies,
genome-wide surveys of cohorts of patients with neurodevelop-
mental disorders (NDs) and congenital anomalies (CAs)
(ND–CAs) for point mutations and structural variations have
greatly advanced our understanding of their genetic etiologies4, 5.
However, even after whole genome sequencing (WGS), no cau-
sative mutation can be identiﬁed in many such cases6. We
hypothesized that some cases of ND–CA that remain refractory
to conventional sequence-based analysis harbor rare epigenetic
aberrations (termed epivariations), which are associated with
dysregulation of normal genome function, and that these would
be missed by the conventional sequencing approaches. We
identify rare epigenetic changes that are absent in thousands of
controls in ~20% of patients with ND–CA. From large-scale
sequencing, population and expression studies, we conclude that
epivariations are: (i) frequently associated with extreme outlier
and mono-allelic gene expression; (ii) generally conserved across
multiple tissues within an individual, validating the use of blood
DNA to study ND–CA; (iii) sometimes occur secondary to cis-
linked regulatory mutations, providing a rationale for interpreting
non-coding genetic variants; (iv) can occur sporadically with a
remarkably high de novo rate, and (v) a subset exhibit non-
Mendelian inheritance, suggesting they are often being reset
between generations by epigenetic reprogramming. We propose
that epivariations likely contribute to the pathogenesis of some
patients with unexplained ND–CAs, and suggest that epigenome
proﬁling represents a promising method for the study of human
disease that complements sequence-based approaches.
Results
Identiﬁcation of epivariations in cases and controls. We studied
a cohort comprising 489 individuals with ND–CA: most had been
previously tested by copy number variation (CNV) microarray,
all had undergone exome sequencing, and some had undergone
WGS, yet no putatively pathogenic mutations had been identiﬁed.
Almost 90% of the patients had an ND, 50% were classiﬁed as
having an autism spectrum disorder, 16% had an epilepsy/seizure
phenotype; 65% also had multiple CA, including congenital heart
defects (CHD) (36%), facial dysmorphisms (29%), growth
anomalies (22%), and micro/macrocephaly (13%) (full details in
Supplementary Data 1). We hypothesized that this cohort
represented an optimal population in which to search for novel
pathogenic epivariations since an underlying genomic abnorm-
ality was suspected, but many common environmental and
genetic causes of ND–CA had been excluded. Methylation pro-
ﬁling in ND–CA samples was performed with the Illumina Inﬁ-
nium Human Methylation 450 BeadChip (450k array). Proﬁles in
each ND–CA sample were compared individually against a
control cohort comprising 1534 unrelated individuals from four
publicly available datasets (GSE36064, GSE40279, GSE42861, and
GSE53045). We also searched for epivariations in two cohorts of
population controls by comparison against this same set of 1534
individuals: 117 families (GSE56105)7 were used to assess the
inheritance of epivariations in controls (Supplementary Data 2);
2711 unrelated individuals (GSE55763)8 were used to assess the
frequency of epivariations in the general population (Supple-
mentary Data 3). We utilized a sliding window approach to
identify epivariations in each sample, deﬁned as 1 kb regions
containing ≥3 probes showing rare outlier methylation absent in
the set of 1534 common control individuals (see Supplementary
Fig. 1 and Methods section). After stringent quality control,
including removal of loci with clusters of poorly hybridizing
probes and extensive manual curation to remove technical and
batch effects, we identiﬁed a total of 143 epivariations in 114
ND–CA samples (i.e., 23% of the probands tested). Twenty per-
cent of the ND–CA cohort carried one epivariation (n= 98),
while 3% of the individuals tested presented two or more epi-
variations (n= 16) (Supplementary Data 4 and Supplementary
Fig. 2).
Using PCR/bisulﬁte sequencing, we attempted orthogonal
conﬁrmation for 70 epivariations. We observed concordant
changes in methylation for 55 of the 58 assays that provided
useful data, yielding a 95% true positive rate for differentially
methylated regions (DMRs) detected by array (Supplementary
Data 5). Allelic analysis demonstrated that these epivariations
represent large methylation changes speciﬁcally on one allele,
consistent with the hypothesis that epivariations represent allelic
events. In most cases, we observed two clusters of largely
methylated and unmethylated reads occurring in approximately
equal proportions (Fig. 1), although in some instances the
interpretation of validation experiments was made complex due
to highly biased allelic representation, presumably reﬂecting
preferential PCR ampliﬁcation of one allele (Supplementary
Fig. 3).
In addition to searching for epivariations in samples with
ND–CA, we also screened two large cohorts of population
controls, identifying a total of 719 DMRs in the 3326 control
samples analyzed (Supplementary Data 2 and 3). Thus, epivaria-
tions are a relatively common occurrence in the human genome,
and are not always associated with any discernable clinical
phenotype. Twenty-four of the epivariations identiﬁed in our
cases with ND–CA were also found in one or more of these
controls, therefore indicating that either these DMRs are
unrelated to the patient phenotype, or perhaps are associated
with incomplete penetrance. However, we observed a 1.2-fold
enrichment in the frequency of epivariations in the 489 ND–CA
samples when compared to 2711 population controls (Supple-
mentary Fig. 2), although this does not reach statistical
signiﬁcance (p= 0.058, two-sided Fisher’s exact test).
Using a combination of 450k arrays and bisulﬁte PCR/
sequencing assays, we were able to assess the inheritance of 57
DMRs identiﬁed in our patients with ND–CA: 33 of the 57
epivariations tested were also present in apparently unaffected
parents, and thus represent inherited events. However, 42% (n=
24) of the epivariations identiﬁed in patients with ND–CA were
absent in both parental samples, and thus occurred as de novo
events. When compared to epivariations found in 117 control
pedigrees7 (Supplementary Data 2), this represents a 2.8-fold
enrichment in the rate of de novo epivariations in cases compared
to controls (p= 0.007, two-sided Fisher’s exact test) (Fig. 2).
Thus, while it is currently unclear whether many of the
epivariations identiﬁed contribute to the phenotypes of the
patients in our study, the paradigm of de novo mutational events
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echoes that observed for other classes of genetic mutation (copy
number and single nucleotide variation (SNV)) deemed patho-
genic in ND and CHD cohorts9, 10.
In addition to their de novo nature, recurrence of mutations
found in unrelated patients with a similar phenotype is
commonly used as a way of assigning signiﬁcant evidence for
the involvement of a speciﬁc gene or locus in disease. We
identiﬁed 12 recurrent epivariations (Supplementary Fig. 4), i.e.,
the same methylation change was identiﬁed in multiple unrelated
probands. Of these, two epivariations encompassed the promoters
of genes known to show altered methylation in congenital disease
(MEG3 and FMR1)6, 11, showing that our approach successfully
detects pathogenic epivariations. The two males identiﬁed with
hypermethylation at FMR1 had phenotypes consistent with a
diagnosis of fragile X, primarily intellectual disability (ID) and
behavioral anomalies. While both had previously been tested by
PCR and reported as normal, subsequent Southern blot testing
conﬁrmed the presence of the classical FMR1 triplet repeat
expansion, although in one case this was an apparent mosaic
event. A third recurrent epivariation coincides with a fragile site
containing a hypermethylated triplet repeat expansion
(FRA10AC1)12 although this, and four other recurrent epivaria-
tions detected in our disease cohort, was also identiﬁed in
population controls, suggesting that they are unlikely to be
pathogenic. One of the novel recurrent epivariations detected
only in our patient cohort was found in two patients with CHD
(Probands 22 and 117), and represents a recurrent hypo-
methylation defect at the promoter—5′ UTR—ﬁrst exon of
MOV10L1, a gene with an embryonic heart-speciﬁc isoform that
interacts with the master cardiac transcription factor NKX2.513
(Fig. 1). One patient with this epivariation atMOV10L1 presented
with double outlet right ventricle, hypoplastic left ventricle,
asplenia, and short stature, while the second presented with
pulmonary stenosis, laryngo-bronchio-tracheomalacia, and foot
polydactyly. Finally, using less stringent criteria for identifying
DMRs (see Methods), we detected methylation defects in 11
probands at 10 imprinted loci14 (Supplementary Fig. 5 and
Supplementary Table 1), 90% of which occurred de novo. Of
note, we observed loss of methylation at two known imprinted
loci that have no prior disease associations (NAA60/ZNF597 in
Probands 6 and 62, and L3MBTL1 in Proband 308), although in
both cases similar losses of methylation were also observed in
population controls, making the pathogenic signiﬁcance of loss of
imprinting at these loci unclear.
Regulatory mutations underlie some epivariations. Based on
previous studies15, 16, we hypothesized that some epivariations
might occur secondarily to an underlying regulatory sequence
mutation. In order to identify mutations disrupting regulatory
elements (e.g., transcription factor binding sites) that might
underlie the methylation changes observed in our cohort, we
performed high-resolution array comparative genomic hybridi-
zation (CGH) and targeted DNA sequencing of 50 DMRs and
their ﬂanking sequences. We detected rare sequence mutations
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Fig. 1 Large gains and losses of DNA methylation identiﬁed in patients with
ND–CA. Plots a, b, and c show β values obtained from Illumina 450k array
for probands (highlighted in green) and 1534 controls (shades of gray
corresponding to ±1, ±1.5, and ±2 standard deviations from the population
mean, represented by the dashed black line; dashed gray lines represent
controls with outlier methylation levels). a Recurrent hypomethylation of
the imprinted locus of MEG3 (hg19: chr14:101290194–101294429) in
Proband 398 (solid green line) and Proband 146 (dashed green line). The
epivariation in Proband 398 is de novo as both mother (red line) and father
(blue line) present methylation proﬁles similar to controls. b Recurrent
hypomethylation at the promoter, 5’ UTR, and ﬁrst exon ofMOV10L1 (hg19:
chr22:50528178–50528751) observed in two unrelated probands: Proband
22 (de novo epivariation) and Proband 117 (inheritance unknown).
c Hypermethylation of ZNF57 in Proband 381. d Pedigree and graphical
representation of the methyl-seq data consistent with allele-speciﬁc nature
of a de novo hypermethylation identiﬁed in ZNF57 is shown. Each plot
shows the methylation pattern for an amplicon, with each row representing
a single bisulﬁte read and each column one CpG in the amplicon. Black
circles are methylated CpGs and white circles unmethylated CpGs. Based
on the presence of a heterozygous SNP within the DMR (hg19:
chr19:2900643), the observed gain of methylation occurs speciﬁcally on
one allele: each pie chart shows the methylated fraction of reads per CpG
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that co-segregated with epivariations and potentially impact
regulatory elements at 24% of the loci tested: six CNVs (Fig. 3 and
Supplementary Fig. 6) and seven SNVs (Supplementary Data 4, 6,
and 7). Where inheritance data from parental samples were
available, we found that all of these rare CNVs and SNVs seg-
regated with the presence of the DMR, suggesting that the epi-
variations occurred secondarily to the underlying sequence
mutation.
Of the rare segregating SNVs detected at DMRs, three were
SNVs within the canonical binding sites for CTCF (CCCTC-
binding factor), a transcription factor with roles in chromatin
organization (Fig. 4), including a de novo SNV that disrupts a
CTCF binding motif in association with a de novo epivariation
(Proband 70) (Supplementary Fig. 7). In each case, the disrupted
CTCF motif was either overlapping or very close to (separation
<1 kb) the DMR. This represents a signiﬁcant enrichment for rare
SNVs disrupting CTCF binding sites in the vicinity of epivaria-
tions when compared to the same regions in other samples in
whom we performed targeted sequencing, but who did not carry
epivariations at these loci (p= 0.0015, two-sided Fisher’s exact
test), strongly implicating rare cis-linked variants in regulatory
sequence as a causative factor underlying some epivariations.
Furthermore, given the low frequency of de novo SNVs and
epivariations in the genome, it is highly unlikely that a de novo
SNV and a de novo epivariation would co-occur at the same locus
in an individual by chance, providing additional support that
some epivariations represent secondary events caused by disrup-
tion of CTCF binding. Using paired methylation and sequence
data from 90 individuals studied by the 1000 Genomes Project
(Supplementary Data 8), we replicated this enrichment for rare
SNVs disrupting CTCF binding motifs around epivariations (p=
0.049, two-sided Fisher’s exact test), identifying two rare CTCF-
disrupting SNVs, one of which co-segregates with the presence of
an epivariation in multiple unrelated individuals. Though readily
detectable by WGS, there is considerable difﬁculty in interpreting
the functional signiﬁcance of variants outside of coding regions.
Thus, we propose that the use of epigenome proﬁling represents a
complementary approach that can provide a rationale for
interpreting non-coding genetic variation.
Functional consequences of epivariations. In order to provide
insight into the biology and functional consequences of epivar-
iations17, we performed studies of gene expression, inheritance,
and tissue conservation using datasets of DNA methylation
(Supplementary Data 9), gene expression (Supplementary
Data 10), and genotype data derived from population controls18–
21. Using paired RNAseq and DNA methylation data in 90 sam-
ples from the 1000 Genomes Project, we veriﬁed that epivaria-
tions encompassing gene promoters were often associated with
large changes in gene expression, with hypomethylation leading
to increased expression and hypermethylation to transcriptional
repression, consistent with the known repressive effects of pro-
moter DNA methylation (p= 9.2 × 10−5, Wilcoxon Rank-Sum
test) (Fig. 5, Supplementary Data 10)22. We also observed that
many hypermethylated epivariations at promoters are associated
with complete silencing of one allele (Supplementary Fig. 8).
While these observations were made in a control cohort, this
suggests that some epivariations have an impact comparable to
that of loss-of-function coding mutations.
Epivariations are generally present in multiple tissues. While
epigenetic proﬁles can vary substantially between cell types23, it is
unclear whether similar cell-speciﬁc variability exists for epivar-
iations. To address that, we analyzed cohorts in which methyla-
tion proﬁles were available from multiple different tissues21. In
samples from the GenCord population, in which methylation
data from ﬁbroblasts, B cells, and T cells sampled from dozens of
newborns are available, by ﬁrst identifying DMRs in T cells, we
observed a very strong concordance for outlier methylation at the
same locus in ﬁbroblasts derived from the same individual
(Spearman rank correlation of 0.75, p= 1.2 × 10−27, Wilcoxon
Rank-Sum test) (Fig. 6, Supplementary Data 9). Similar con-
cordance for outlier methylation at epivariations was also
observed between ﬁbroblasts and B cells.
A similar trend for conservation of epivariations across
multiple different post-mortem tissues was also observed in a
second cohort24. Here, epivariations found in blood were nearly
all visible in multiple other somatic tissues sampled from the
same individual (Supplementary Fig. 9). Thus, we conclude that
the majority of epivariations are constitutive events found in
multiple tissues. This provides conﬁdence that epivariations of
relevance for ND–CA can be detected using DNA extracted
from readily available sources such as peripheral blood
leukocytes.
Evidence for non-Mendelian inheritance of epivariations.
Despite strong evidence that some of the epivariations we
observed are secondary events related to the presence of an
underlying sequence change (Figs. 3 and 4), we were unable to
detect cis-linked sequence mutations associated with the majority
of epivariations in our cohort, suggesting that these might instead
represent primary epivariations that arose sporadically. As the
mammalian genome undergoes several rounds of demethylation
and remethylation during gametogenesis, embryonic and somatic
development25, theoretically there is considerable potential for
primary epivariations to be reset to the default state. We therefore
assessed how often epivariations are stably transmitted between
parents and their offspring. Using a large control cohort com-
prising 117 nuclear families7, we studied the heritability of epi-
variations between generations, identifying 47 epivariations
segregating within these pedigrees. We observed a marked
deviation from the expectations of Mendelian inheritance, with
only 32 instances of parent–child transmission in 95 informative
meioses; signiﬁcantly fewer than the Mendelian expectation of
47.5 transmissions (p= 0.027, two-sided Fisher’s exact test)
(Supplementary Data 2). Therefore, this apparent reduction in
heritability indicates that primary epivariations often exhibit non-
Mendelian inheritance, and suggests they are frequently reset
between generations by epigenetic reprogramming26–28.
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Fig. 2 A signiﬁcant excess of de novo epivariations found in patients with
ND–CA. We observed a 2.8-fold enrichment for de novo epivariations in
cases (n= 24 out of 57) when compared to controls (n= 6 out of 40)
(p= 0.007, two-sided Fisher’s exact test)
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Discussion
In this study, we set out to investigate the prevalence, causes, and
consequences of epigenetic defects in the human genome, and to
study their potential role in the etiology of ND–CA disorders. By
performing epigenome proﬁling in a large cohort of 489 patients
with diverse ND–CA, all of whom had previously undergone
microarray testing and/or exome or genome sequencing, in
addition to analyzing >5000 population controls, we demonstrate
that epivariations are a relatively frequent occurrence in the
human population. Subsequent analysis of cell lines showed that
the presence of epivariations is often associated with large
changes in the expression of cis-linked genes, indicating func-
tional consequences on the genome. Furthermore, we demon-
strated that epivariations are generally conserved across multiple
tissues, validating the use of peripheral blood for the studies of
ND–CA.
We observed both recurrent epivariations in cases that were
absent in thousands of population controls, and a signiﬁcant
excess of de novo epivariations in cases compared to controls,
both of which are hallmarks often associated with pathogenic
variants. Despite this, the pathogenic signiﬁcance of many of the
epivariations we identiﬁed remains uncertain. For example, in
many cases, epivariations were inherited from apparently unaf-
fected parents, suggesting that they are unlinked to the observed
phenotype. While it is likely that the presence of some epivaria-
tions we observed in ND–CA cases is unrelated to patient phe-
notype, we note that not all inherited events are benign, and there
are many examples of rare inherited sequence variants that show
variable penetrance29.
Studies of the inheritance of epivariations in families showed
that they can occur de novo at very high frequency (up to 42%),
yet also show signiﬁcantly reduced heritability compared to
Mendelian expectations, suggesting that they are often reset
during meiosis. However, in contrast to this dynamic process of
frequent gain and loss, targeted sequencing and array CGH
identiﬁed segregating rare sequence variants that disrupt
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Fig. 3 Detection of rare CNVs by targeted sequencing of epivariations and their ﬂanks. Proband 121 carries a maternally inherited DMR at the PDCD2 locus.
We identiﬁed a maternally inherited heterozygous 4061 bp deletion ﬂanking the DMR. Two other similar examples are shown in Supplementary Fig. 6
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annotated regulatory elements associated with 24% of the epi-
variations we investigated, indicating that a subset are likely
secondary events caused by underlying sequence variations. Thus
our data are consistent with a model in which some epivariations
are primary events that occur sporadically, but are often reset
during the waves of epigenome remodeling that occur during
meiosis and early embryonic development, while others are sec-
ondary events that occur as a result of cis-linked regulatory
sequence mutations. Consistent with this, previous studies in
humans27 and mouse26, 28 have shown that primary epimutations
are often reset during meiosis, while secondary epivariations have
been observed to remain stable through multiple generations30.
In addition to mutations that disrupt regulatory elements such
as TF binding sites, expansions of GC-rich tandem repeats can
also result in local DNA hypermethylation. Indeed, we identiﬁed
multiple individuals with gains of methylation at known CGG
repeats, including FMR1/FRAXA3 (two cases), XYLT1/FRA16A
(one case)31, FRA10AC1/FRA10 (two cases and nine controls)32,
and DIP2B/FRA12 (one control)33. Both individuals with FMR1
hypermethylation were shown to carry the classic CGG expansion
that causes Fragile X, and although not tested, it is likely that the
gains of methylation observed at the other three known fragile
sites are also caused by similar repeat expansions. While our
targeted sequencing experiments of other epivariations did not
identify any novel tandem repeat expansions, this class of
mutation is difﬁcult to detect with short-read sequencing. Thus, it
remains possible that some of the hypermethylated epivariations
we observed might be caused by this mechanism.
Previous studies have made attempts to investigate the pre-
valence of epigenetic changes in patients with ND–CA. Kolarova
et al.34 compared the DNA methylation proﬁles of 82 patients
against 19 controls, identifying a total of 157 DMRs. Consistent
with our own ﬁndings, Kolarova et al.34 also identiﬁed patients
with hypomethylation defects of MEG3 and MOV10L1. While
loss of imprinting at MEG3 is a known cause of Temple syn-
drome, the recurrent observation of hypomethylation of
MOV10L1 is signiﬁcant (total n= 3 of 571 cases versus 0 of 4878
controls, p= 0.001, Fisher’s Exact test), and provides additional
evidence implicating this locus with developmental defects.
Similarly Aref-Eshghi et al.35 assessed methylation patterns in a
total of 528 samples, identifying altered methylation levels at
several imprinted loci that were absent in controls. Consistent
with our own study, their cohort included two patients with
hypermethylation of HM13, thus demonstrating this as another
recurrent alteration found in patients with ND–CA, and sug-
gesting that this may be an imprinting disorder.
Our study shows that epivariations are a relatively common
feature in the human genome, that some are associated with
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changes in the local gene expression, and raises the possibility
that they may be implicated in the etiology of developmental
disorders. In an era when WGS is being applied to many thou-
sands of human genomes, epivariations represent a class of
genetic variation that remains undetectable by purely sequence-
based approaches. We anticipate that future studies exploring the
relationship between sequence variation and epigenetic state will
further illuminate the regulatory architecture of the human
genome, providing novel insight into the consequences of non-
coding mutations.
Methods
Patients. A total of 489 patients with idiopathic sporadic NDs and/or multiple CAs
with an average age of 10 years (range: newborn to 54 years), comprising 32%
females and 68% males, were enrolled in the study (Supplementary Table 1).
Inclusion criteria entailed the patient having undergone previous exome sequen-
cing, with no pathogenic ﬁndings identiﬁed. Many samples tested had also
undergone a number of locus-speciﬁc tests for common causes of ND–CA, such as
Fragile X testing, genomic microarray (Affymetrix 250k SNP array, or Agilent array
CGH), and/or WGS. This cohort results from a collaborative effort of multiple
centers/groups, namely: 163 trios from The Seaver Autism Center for Research and
Treatment at the Icahn School of Medicine at Mount Sinai (USA), 155 trios from
the Pediatric Cardiac Genomics Consortium under an approved ancillary study of
the PCGC (USA), 94 trios from the Medical Genetics Center Jacinto Magalhaes
and the Life and Health Sciences Research Institute (Portugal), and 77 trios from
the Nijmegen Medical Center (Netherlands). The main reason for referral was
intellectual disability and/or autism spectrum disorder. The majority of patients
also presented multiple CAs and/or facial dysmorphisms. A complete list of phe-
notypic ﬁndings is shown in Supplementary Table 1. This study has been con-
ducted in accordance to the rules of the Institutional Review Boards (IRB) of The
University of Minho, Portugal, Radboud University Medical Center, The Nether-
lands, and The Icahn School of Medicine at Mount Sinai, under HS#: 12–00749.
Informed consent was obtained from subjects where required. Some samples were
obtained as residual DNA remaining after clinical testing, and after anonymization
were thus not classiﬁed as Human Subjects.
Our control cohort resulted from the merger of publicly available datasets taken
from the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/). In total,
we utilized data from 1534 unrelated individuals from the general population
without ND–CA who had DNA extracted from peripheral blood and undergone
proﬁling with the Illumina 450k array (GSE36064, GSE40279, GSE42861,
GSE53045)36–39. GSE36064 focused on a healthy pediatric cohort, GSE40279
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analyzed a cohort with a large age range as the goal was to understand epigenetics
of human aging, GSE42861 enrolled individuals with rheumatoid arthritis as well
as healthy individuals, and GSE53045 included adults who smoked as well as were
non-smokers. In total, our control cohort had 60% females and 40% males with an
average age of 56 years, range: 1–101 years old. From the samples included in the
GEO entries, we excluded a small number of outlier individuals based on principal
component analysis (PCA) of autosomal probes. By sequentially comparing each
control sample against the remainder using our DMR calling pipeline (see below),
we also removed those samples that reported >10 DMRs. A ﬁnal list of the 1534
controls utilized is available on request.
In order to compare the rate of de novo epivariations in probands to a cohort of
healthy individuals, we used dataset GSE56105 from GEO, which comprised 614
healthy individuals from 117 families (mother, father, each with 2–4 children). In
order to assess the frequency of epivariations in the general population, we used the
dataset GSE55763 from GEO, which comprised 2711 unrelated individuals (40%
Type 2 diabetes cases, 60% population controls). Each proﬁle was generated using
the DNA extracted from peripheral blood followed by hybridization to the Illumina
450k array7, 8.
Methylation array. Genome-wide DNA methylation proﬁling was performed
using Human Methylation 450k BeadChips (Illumina Inc., San Diego, CA, USA)
according to the manufacturer’s recommended protocol40. Patient samples were
processed in six different batches using three different facilities: New York Genome
Center (three batches), Genomics Core of the Icahn School of Medicine at Mount
Sinai (two batches), and Genetics lab at Northwell Health (one batch). We
observed no signiﬁcant differences in the number of DMRs called per sample, or
the rates of secondary validation based on array batch or processing center.
Quality control and normalization. Raw data ﬁles with β values, color, intensity,
and detection p-values per probe were obtained from the genomics facilities.
Quality control steps entailed performing a gender check, a screen for potential
regions of homozygous deletion, PCA plots, and density plots of M values. Beta
values from autosomes and β values from chromosome X were processed and
analyzed separately.
We inferred patient gender by calculating both the mean p-value of
chromosome Y probes, and the mean β value of chromosome X probes per sample,
and compared these to the patient records. A mismatch between the array-inferred
gender and the reported patient gender was detected in four samples: these samples
were removed from downstream analysis and the published GEO entry.
As the 450k array utilizes hybridization of DNA to infer a methylation value per
probe, regions of homozygous deletion where probes have no target DNA to
hybridize often yield very low signal. In such regions of homozygous deletion,
reported β values are often highly erratic, and thus can easily appear as outlier
values when compared to the rest of the population, yielding potential false-
positive DMRs in our analysis. We assessed the presence of putative homozygous
deletion regions by identifying clusters of probes with failed detection p-values. For
a high-quality 450k array hybridization, typically <0.1% of autosomal probes yield
detection p-values >0.01. Thus, clusters of multiple probes in any one sample with
failed detection p-values (p >0.01) should be extremely rare. The perl script
arguments were set to ﬂag 3 kb windows where three or more probes yielded
detection p >0.01 in each sample. In total, across the 489 probands, we detected 182
putative regions of homozygous deletion (Supplementary Data 11). By comparing
these putative CNVs with publicly available datasets41 (minor allele frequency,
MAF ≥5%), we observed that 81% of clusters of probes with failed detection p-
values corresponded to common CNV loci or intergenic space, validating this as an
appropriate method. Regions identiﬁed as putative homozygous deletion in each
sample were then excluded from the list of DMR calls.
PCA and density plots of M values were obtained with the lumi and
methylumi R packages42. We excluded one sample from downstream analysis
because it was a clear outlier by PCA. Two additional samples (Proband 488 and
Proband 489) were removed from the analysis of chromosome X because they were
clear outliers by PCA based on chromosome X data.
After removal of probes with failed detection p-values (p > 0.01) in each sample,
we performed color correction, background correction, and quantile normalization
of β values across all probands control samples using lumi and methyllumi. Finally
we performed normalization to account for the different data distributions of
Inﬁnium type I and type II probes using the BMIQ package43.
Identiﬁcation of candidate DMRs. Identiﬁcation of putative DMRs was per-
formed using a custom perl script (available at https://github.com/AndyMSSMLab/
Scripts/tree/master). We utilized a sliding window approach to individually com-
pare the methylation proﬁle in each proband against the entire control cohort,
detecting regions of robust outlier methylation represented by multiple indepen-
dent probes with extreme methylation values, including at least one probe with
methylation values well outside that observed in any control sample. This was done
as single probes can present outlier values due to technical array artifacts, hybri-
dization artifacts such as the presence of underlying sequence variants, or the
presence of C>T mutations at the CpG being assayed. Stringent thresholds for
calling DMRs were set as follows:
● Hypermethylation: the proband presents, in a 1-kb window, probes that fulﬁll
both of the following criteria:
(i) At least 3 probes that each have β values above the 99.9th percentile of
the control distribution for that probe, and are ≥0.15 above the control mean.
(ii) At least 1 probe with a β value ≥0.1 above the maximum observed in
controls for that probe.
● Hypomethylation: the proband presents, in a 1-kb window, probes that fulﬁll
both of the following criteria:
(i) At least 3 probes that each have β values below the 0.1th percentile of
the control distribution for that probe, and are ≥0.15 below the control mean.
(ii) At least 1 probe with a β value ≥0.1 below the minimum observed in
controls for that probe.
All DMRs were manually curated to remove the loci that were deemed false-
positive calls. Despite performing probe-level ﬁltering and multiple rounds of
normalization of the array data, such measures are imperfect and do not remove all
probes that show aberrant signals due to underlying technical or biological effects.
We observed both systematic batch effects, and also sporadic false positives in
single samples that were ﬁltered, as follows:
(i) Batch effects, i.e., technical differences due to arrays being processed in separate
groups, were sometimes observed between cases and controls. Here, it was usually
observed that there was either a systematic shift in β values reported by one or more
probes within a region between arrays processed in different batches. In some cases,
the mean of each batch was signiﬁcantly different, with every sample showing a shift,
whereas in other cases the means of the two populations remained similar, but a
subset of the samples in one batch showed a gradient of deviations, with the β values
of multiple cases lying in the extreme tail of the control distribution.
(ii) In some cases, while 3 probes within a 1-kb region were identiﬁed as outliers,
the outlier probes were not in a contiguous block as would be expected for a true
methylation change, and were interspersed with other probes that showed no
difference compared to the control population. We interpreted these signals as likely
random groupings of individual probes that each yielded outlier beta values for some
other reason, e.g., rare underlying variations that inﬂuenced probe performance, or
poor hybridization performance of individual probes. Indeed, we identiﬁed that many
such cases were due to regions of homozygous deletion as indicated by clusters of
probes with failed array detection p-values (Supplementary Data 11).
We observed that 98.6% of the probands presented less than 10 DMRs. Due to a
clear increase in the rate of false-positive DMRs as assessed by manual curation,
samples with >10 DMRs were excluded (Supplementary Fig. 10). Only the 143
epivariations that were deemed true positive by both researchers were kept for
downstream analysis (Supplementary Fig. 2 and Supplementary Data 4). All genomic
coordinates are in build GRCh37/hg19. We identiﬁed 12 recurrent epivariations
(Supplementary Fig. 4). Methylation proﬁles of 614 healthy individuals from 117
families (GSE56105) were subject to the same analysis, comparing individual
methylation proﬁles against 1534 controls to search for outlier DMRs (Supplementary
Data 2). Taking into account the pedigree information, assessment of epivariation
inheritance was performed by inspection of data plots of all family members at the
DMR locus; 2711 unrelated individuals (GSE55763) were subject to the same pipeline
for identiﬁcation of DMRs (Supplementary Data 3).
Epivariation calling at imprinted loci. To identify epivariations affecting imprinted
loci, a total of 763 450k array probes mapping to 50 imprinted loci were selected from
Monk et al.44 and Joshi et al.14. The mean methylation level was calculated in each
proband and control by averaging β values for all probes within each imprinted locus.
For each proband, methylation changes were considered as epivariations when either
the mean methylation level showed a difference greater than 3 standard deviations
from the mean of controls, or when the mean β value was >0.8 or <0.2. Epivariations
identiﬁed in imprinted loci are listed in Supplementary Table 1.
Bisulﬁte sequencing. In order to assess the accuracy of our identiﬁcation of
putative epivariations from array data, we performed secondary validation
experiments using bisulﬁte PCR amplicon sequencing. Validation studies were
performed in both the proband and parental DNAs (where available) to determine
if they were (i) genuine regions of outlier methylation, (ii) inherited from a phe-
notypically normal parent (and therefore likely unrelated to patient phenotype), or
(iii) de novo (and therefore likely pathogenic). Finally, bisulﬁte sequencing has the
additional advantage of being able to determine if the methylation change occurred
on one or both alleles, which is important given that the epivariation paradigm
predicts that most pathogenic changes will present as mono-allelic gains or losses
of methylation.
Samples were processed at the Herbert Irving Comprehensive Cancer Center
Epigenetics Medical Center, Columbia University Medical Center. Genomic DNA
was bisulﬁte treated and then subjected to targeted sequencing. Primers were
designed using MethPrimer, bisulﬁte-converted DNA was ampliﬁed by PCR,
followed by next-generation sequencing (NGS) (Illumina MiSeq). Sample
preparation for MiSeq was performed on a Fluidigm AccessArray high-throughput
PCR machine with sample bar-codes incorporated in a second round of PCR.
Allele-speciﬁc methylation was assessed where coverage was >100 reads. Libraries
prepared by this method were then subjected to NGS on the Illumina MiSEQ (2 ×
150 bp) platform, which scores net methylation in each amplicon based on the ratio
of C to T bases at CpG positions. For each amplicon and sample, methylation
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percentages (Methylated reads/Total reads) averaged across the covered CpGs
(>100×) were provided.
Seventy epivariations were selected for validation with this methodology
(Supplementary Data 5). Eleven assays failed to work. Of the remainder, we veriﬁed
that 33 epivariations were inherited (67% maternal and 33% paternal), 24 were de
novo, and 2 were true positives but their inheritance was not assessed (Supplementary
Data 4). In some instances, the interpretation of validation experiments was made
complex due to highly biased allelic representation, presumably reﬂecting preferential
PCR ampliﬁcation of one allele (Supplementary Fig. 3).
To conﬁrm the epivariations at imprinted loci, 2 μg of DNA was treated with
sodium bisulﬁte and puriﬁed using the EpiTect Bisulﬁte kit (Qiagen, Germantown
MD). Bisulﬁte PCR for each candidate region was performed on 2 μl of bisulﬁte-
treated DNA using HotStarTaq DNA Polymerase (Qiagen, Germantown MD) and
speciﬁc primers. After ampliﬁcation, PCR products were cloned into TOPO TA
vector (Invitrogen, Carlsbad, CA) and transformed into chemically competent
TOP10 cells (Invitrogen, Carlsbad, CA) for subsequent sequencing using M13R
primers (Supplementary Fig. 5).
Agilent custom designed array. In order to identify CNVs overlapping or
adjacent to epivariations that could underlie the methylation change, we designed a
custom ultra-high-resolution CGH array speciﬁcally targeting 28 DMRs and ±600
kb of their ﬂanking sequences. At each epivariation locus to be assayed for CNVs,
we selected a mean density of 1 probe per ~150 bp ± 100 kb of each DMR, and
more sparse coverage (mean density of 1 probe every ~600 bp) extending a further
500 kb upstream and downstream. Normalization probes spaced throughout the
autosomes and additional control probes on chromosomes X and Y were also
included in the array. The custom array was designed and ordered through Agi-
lent’s online portal (https://earray.chem.agilent.com/earray/). DNA samples were
processed in the Cytogenetics and Cytogenomics Laboratory of the Icahn School of
Medicine at Mount Sinai. The epivariations assayed for CNVs with this method are
listed in Supplementary Data 6.
Targeted sequencing of epivariations. In order to identify SNVs within DMRs or
their ﬂanking sequences that could underlie methylation changes, we performed
targeted sequencing of 36 DMRs (Supplementary Data 4), including an additional ±75
kb of sequence from each ﬂank, using a custom sequence capture assay and a
HiSeq2500 instrument. Brieﬂy, library preparation entailed shearing DNA using a
Bioruptor (Diagenode, Denville NJ) to a mean fragment size of 300 bp, use of the
KAPA LTP prep kit and barcoding the DNA with NextFLEX (Bioo Scientiﬁc, Austin
TX). Capture was performed with a custom oligonucleotide DNA capture kit (Nim-
blegen, Madison WI). NGS was performed using paired-end 150 bp reads generated
with an Illumina HiSeq 2500. Thirty-six samples were multiplexed per sequencing
lane, and were processed in the Genomics Core of New York University.
Paired-end reads were mapped against the human reference genome (hg19)
using BWA-MEM45 (https://github.com/lh3/bwa, v0.7.12) with default parameters.
Duplicate reads were marked using Samblaster46 (https://github.com/
GregoryFaust/samblaster, v0.1.22). Finally, we used the Genome Analyzer Tool
Kit47 (GATK: https://software.broadinstitute.org/gatk/documentation/article.php?
id= 6201, v3.3.0) to perform indel realignment and base quality score recalibration
as described in GATK best practices48. For manipulating SAM/BAM ﬁles and for
intermediates steps such as sorting and indexing, we used Sambamba49 tools
(https://github.com/lomereiter/sambamba, v0.5.5). Samblaster was used to generate
the ﬁle containing discordant reads and split reads, which is required by Lumpy for
structural variation calling.
Variant discovery was performed using GATK’s n+1 joint genotyping protocol
(https://software.broadinstitute.org/gatk/documentation/article.php?id= 3893).
The protocol involves multiple steps. Initially, the gVCF ﬁle was created
individually for each sample using the haplotype caller utility. Next, joint
genotyping was performed on all samples together and a single vcf ﬁle generated.
In all steps, we restricted genotyping to the targeted loci. The resulting variants calls
were annotated with CADD50 scores (http://cadd.gs.washington.edu/, v1.3), MAF
from the 1000 Genomes Project (phase 3) using Annovar51 (http://annovar.
openbioinformatics.org/en/latest/, v2016Feb01). Rare variants (1000 Genomes
MAF < 1%) were further annotated with transcription factor (TF)-binding sites
predicted by the CENTIPEDE algorithm52, and DNAseI hypersensitivity sites from
the ENCODE project53 (Supplementary Data 7). Where parental genotypes were
available, concordance of inheritance between an epivariation and SNP were used
to ﬁlter candidates. In order to assess if these rare SNVs were potentially disrupting
TF-binding sites (TFBS), we used the UCSC Genome Browser track “Transcription
Factor ChIP-seq (161 factors) from ENCODE with Factorbook Motifs”54 (http://
hgdownload.soe.ucsc.edu/goldenPath/hg19/database/factorbookMotifPos.txt.gz, 16
March 2014 release), which included canonical TFBS motifs for 129 TFs.
Putative duplication and deletion structural variants (SV) were called jointly
using Lumpy55 (https://github.com/arq5x/lumpy-sv, v0.2.12). Lumpy identiﬁes SV
breakpoints, which were then genotyped using a Bayesian genotyper, SVTyper56
(https://github.com/hall-lab/svtyper, v0.0.4). SVs with allele balance (AB) <0.1,
read support <5, and genotype quality <30 were removed. Also all sites genotyped
as missing (./.) or homozygous ref (0/0) were removed. Further, SVs present in
>10% of samples were removed. The resulting set of ﬁltered SVs were visually
validated using Integrative Genomics Viewer (IGV)57 (Fig. 3).
Epivariations in B cells, T cells, and ﬁbroblasts. We obtained raw DNA
methylation data generated using the Illumina 450k Human Methylation BeadChip
from the Gencord cohort from the EMBL-EBI European Genome–Phenome
Archive (https://www.ebi.ac.uk/ega/) under accession number EGAS00001000446,
representing 107 ﬁbroblast cultures, 66 T-cell cultures, and 111 immortalized B-cell
cultures derived from a cohort of newborns21. As described above, we performed
lumi and BMIQ normalization. Given that we lacked a large set of control samples
of matched cell type for comparison, DMRs in each sample were identiﬁed as
outliers relative to the rest of the population, using a 1-kb sliding window. In each
window, we required at least 3 probes with β value ≥0.15 the maximum, or ≥0.15
below the minimum, of that observed in all other individuals. Based on the β values
of each probe located within the 1 kb DMR loci, we calculated the population rank
of each individual carrying an epivariation deﬁned in T cells and ﬁbroblast
methylation proﬁles (Supplementary Data 9).
Gene expression studies in 90 lymphoblastoid cell lines. We used normalized
methylation data for a ﬁltered set of 443,498 probes in 90 samples analyzed as part
of the 1000 Genomes Project for which both variant calls and RNAseq data were
also available (GEO GSE39672)19, 20. DMRs were called using an outlier approach
using a 1-kb sliding window, with at least 3 probes with β value ≥0.15 the max-
imum, or ≥0.15 below the minimum, observed in the other 89 individuals. RNAseq
(http://www.ebi.ac.uk/arrayexpress/ﬁles/E-GEUV-1/analysis_results/) and SNV
data18 were obtained and used to measure total gene expression, and allelic
expression levels based on heterozygous transcribed SNVs. For the latter, at each
transcribed SNV position with at least 7 overlapping reads, we made counts of the
number of reads containing reference and alternate alleles. In total, there were
300,111 sites within Refseq gene annotations with at least one individual carrying a
heterozygous SNV with read depth ≥7. We linked each DMR with associated genes
based on physical overlap with gene promoter regions, deﬁned as ±2 kb from the
annotated transcription start site (TSS) (Supplementary Data 10).
Analysis of SNVs around DMRs in 90 lymphoblastoid cell lines. We down-
loaded SNV data for 90 controls from the 1000 Genomes Project (ftp://
ftp.1000genomes.ebi.ac.uk/vol1/ftp/phase3/integrated_sv_map/ALL.wgs.
integrated_sv_map_v2.20130502.svs.genotypes.vcf.gz.). Using the coordinates of
each DMR called in these 90 samples, we extracted SNVs located within ±5 kb of
each DMR, yielding a total of 20,398 DMR-SNV pairs. Variants were then ﬁltered
to retain only those with MAF < 0.1% in the total 1000 Genomes population
(Supplementary Data 8), and annotated for the overlapping TFBS based on
ENCODE/Factorbook data, as described above. TFBS enrichment analysis utilized
the 89 individuals without a DMR as background for each test.
Conservation of epivariations across multiple tissues. We downloaded from
GEO (GSE48472) the methylation proﬁles generated using the Illumina 450k array
from ﬁve deceased individuals, each proﬁled in six different tissues (peripheral
blood, liver, skeletal muscle, pancreas, omental fat, and spleen)24. Data for each
tissue were ﬁltered and normalized separately, following the same approach as used
for patient methylation proﬁles, as described above (see “Methylation array”). For
the peripheral blood data, we then quantile normalized β values with those for the
1534 controls. DMRs were then called in each of the six blood samples using the
same approach as described above (see “Methylation array”). For each DMR
observed in blood, we generated plots of these loci and manually curated for
concordance in the other available tissues (Supplementary Fig. 9).
Code availability. Computer code used in this study is available on GitHub:
https://github.com/AndyMSSMLab/Scripts/tree/master
Data availability. The methylation array data used in this publication have been
deposited in Gene Expression Omnibus (GEO) under accession GSE89353 (https://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89353).
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